Zacks Research Issues Positive Forecast for TBPH Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Research analysts at Zacks Research lifted their Q2 2026 earnings estimates for Theravance Biopharma in a report released on Monday, January 13th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of ($0.11) for the quarter, up from their previous estimate of ($0.12). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share.

Theravance Biopharma Trading Up 0.9 %

Shares of Theravance Biopharma stock opened at $8.61 on Thursday. The business’s fifty day moving average price is $9.48 and its 200 day moving average price is $8.90. Theravance Biopharma has a twelve month low of $7.44 and a twelve month high of $10.44.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The company had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $16.11 million. During the same period in the prior year, the business earned ($0.17) EPS.

Insider Activity

In other news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now owns 322,743 shares of the company’s stock, valued at approximately $2,904,687. This trade represents a 1.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC raised its holdings in shares of Theravance Biopharma by 279.9% during the 3rd quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock valued at $529,000 after buying an additional 48,316 shares during the period. Squarepoint Ops LLC acquired a new stake in Theravance Biopharma during the 2nd quarter valued at $986,000. Bank of Montreal Can increased its stake in Theravance Biopharma by 141.0% during the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock worth $1,414,000 after buying an additional 93,702 shares during the period. Algert Global LLC acquired a new position in Theravance Biopharma in the 3rd quarter worth $851,000. Finally, Dimensional Fund Advisors LP boosted its position in Theravance Biopharma by 38.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock valued at $2,800,000 after buying an additional 91,679 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.